Although molecular targeting drugs, such as epidermal growth factor receptor tyrosine kinase inhibitor and anaplastic lymphoma kinase inhibitor, have recently been used to treat NSCLC, these agents can cause an exacerbation of ILD as an adverse effect. The gene discussed is ALK; the disease is non-small cell lung carcinoma.